Verastem (VSTM) Set to Announce Earnings on Thursday

Verastem (NASDAQ:VSTM) is expected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.4730) per share and revenue of $26.57 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Verastem (NASDAQ:VSTM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. The company had revenue of $40.08 million during the quarter, compared to the consensus estimate of $22.88 million. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. On average, analysts expect Verastem to post ($1.51) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

Verastem Stock Performance

Shares of Verastem stock opened at $9.77 on Wednesday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25. Verastem has a 1 year low of $3.43 and a 1 year high of $10.82. The firm’s 50-day simple moving average is $8.27 and its 200-day simple moving average is $6.21. The firm has a market cap of $884.77 million, a PE ratio of -3.67 and a beta of 0.45.

Insider Buying and Selling at Verastem

In other Verastem news, CEO Dan Paterson sold 44,121 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $8.00, for a total transaction of $352,968.00. Following the sale, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at approximately $5,221,696. This represents a 6.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,742 shares of company stock worth $373,920 over the last 90 days. 1.94% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on VSTM shares. Wall Street Zen raised Verastem from a “sell” rating to a “hold” rating in a report on Sunday, September 27th. Benchmark restated a “buy” rating on shares of Verastem in a research note on Friday, October 16th. Weiss Ratings downgraded Verastem from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 15th. Guggenheim set a $12.00 target price on Verastem and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Verastem in a research report on Monday, October 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Verastem presently has an average rating of “Moderate Buy” and an average target price of $16.67.

Verastem Company Profile

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company’s research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem’s leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.